IMPORTANCE Pathogenic variants in LRRK2 are a relatively common genetic cause of Parkinson disease (PD). Currently, the molecular mechanism underlying disease is unknown, and gain and loss of function (LOF) models of pathogenesis have been postulated. LRRK2 variants are reported to result in enhanced phosphorylation of substrates and increased cell death. However, the double knockout of Lrrk2 and its homologue Lrrk1 results in neurodegeneration in a mouse model, suggesting that disease may occur by LOF. Because LRRK2 inhibitors are currently in development as potential disease-modifying treatments in PD, it is critical to determine whether LOF variants in LRRK2 increase or decrease the risk of PD.
P arkinson disease (PD) is a neurodegenerative disease that affects multiple brain regions, including dopaminergic neurons in the substantia nigra, and results in a complex disease with motor and nonmotor symptoms. 1 Parkinson disease has a large genetic component, with LRRK2 being one of the most commonly mutated genes in the autosomal dominant and sporadic forms. [2] [3] [4] One pathogenic LRRK2
variant (p.G2019S) is estimated to be present in approximately 1% of all cases with PD and up to 39% of cases in some populations. [5] [6] [7] The LRRK2 locus has also been associated with idiopathic PD by genome-wide association studies, indicating that LRRK2 is a pleomorphic risk locus where multiple variants can exist that modify the risk of PD, presumably by overlapping mechanisms.
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LRRK2 encodes a large multidomain protein ( Figure 1 ) that has been suggested to play roles in many cellular processes, including vesicular trafficking, microtubule binding, autophagy and mitophagy. 8 Pathogenic LRRK2 variants lead to enhanced phosphorylation of substrates and increased cell death, suggesting that kinase inhibitors block this gain of function and may be used therapeutically for PD. 9, 10 However, a recent report 11 suggested that knockout of Lrrk2 and its homologue, Lrrk1, results in loss of dopaminergic neurons and α-synuclein pathologic change in a mouse model. Although LRRK1 variants have not been associated with PD or PD age of onset by genome-wide association studies or other analyses, LRRK1 could act as a modifier of LRRK2-associated PD owing to its sequence similarity. LRRK2 variants may cause PD through a type of loss of function (LOF), mediated by haploinsufficiency or a dominant negative mechanism, which would invalidate kinase inhibitors as a potential treatment. To investigate this possibility in humans, we identified LOF variants in LRRK1 and LRRK2 in a large series of cases with PD and control individuals and examined protein expression from several LRRK2 LOF variant carriers.
Methods
Next-generation sequencing data were obtained from 11 095 cases with PD and 12 615 controls in 5 exome and resequencing data sets (eTable 1 in the Supplement). Data processing was performed as previously described, with variants filtered for a minimal read depth of 20, genotype quality score of greater than 20, and an alternate allele ratio of greater than 25%. 7 All LOF variant carriers were also screened for known pathogenic LRRK2 variants, and none were detected. Variants were collapsed per gene owing to low frequencies and because LOF variants should result in haploinsufficiency. In addition, combined multivariate and collapsing and optimized sequence kernel association burden tests were performed per gene. 12 Lymphoblastoid cell lines (LCLs) were obtained from the Coriell Institute, Camden, New Jersey (https://www.coriell.org/) and cultured using standard practices. Details can be found in eMethods in the Supplement. Data were collected from 2012 through 2017. All samples were collected under informed consent procedures approved by the institutional review board of each collecting institution.
Statistical Analysis of LOF Variants
To evaluate whether there are statistical differences between cases and controls in the frequency of LRRK1 and LRRK2 LOF variants we performed a number of tests using R and RVTESTS (version 20171009 
Results
The study population included 11 095 cases with PD and 12 615 controls. From these, we identified 13 cases and 11 controls who carried an LRRK2 LOF variant (Table) . The resulting frequency is 0.117% in cases and 0.087% in controls (odds ratio [OR], 1.48; SE, 0.431; 95% CI, ; P = .36). Sixteen distinct LRRK2 LOF variants include 10 stop-gain variants, 3 frameshift insertions, and 3 frameshift deletions (Table) . Six variants were novel (not present in the Genome Aggregation Database [gnomAD]; http://gnomad.broadinstitute.org/), whereas the remaining 10 were previously identified (Table) . Burden and case-control association tests showed no significant difference in frequency of LRRK2 LOF variants, suggesting that LOF variants are not associated with PD (eTable 6 in the Supplement). These tests have 85% power to identify large causal effects (OR, >4.5). If LRRK2 LOF variants were a direct cause of PD, then we would expect them to have large ORs, and hence diminished power does not affect our conclusions. Because LRRK1 is not a known cause of PD, it was only covered in the whole-exome sequencing data set; therefore, our analysis is based on 2440 cases and 5774 controls. We identified 5 cases and 8 controls carrying an LRRK1 LOF variant, resulting in a frequency of 0.205% in cases and 0.139% in controls (OR, 1.48; SE, 0.571; 95% CI, ; P = .49). These frequencies are slightly higher than those for LRRK2, but with fewer samples we cannot directly evaluate whether this proportion is more than expected by chance. Five distinct LRRK1 LOF variants included 1 stop-gain and 4 frameshift deletions (Table) . Four variants were novel, whereas one was previously identified in gnomAD at a frequency of 0.101%. Five homozygous carriers of this allele have been described in gnomAD, implying that presumably healthy individuals lack the normal LRRK1 protein. Burden and case-control association tests for PD show no significant difference in LRRK1 LOF variant frequency (eTable 6 in the Supplement). Owing to the smaller sample size, LRRK1 association tests had 70% power to identify large effects (OR, >6.0). Although the ORs are reduced compared with those for LRRK2, we would still expect that causative LOF variants would have a large OR. Therefore, this study is powered well enough to detect those differences between cases and controls.
We compared LRRK2 protein levels in individuals with and without LRRK2 LOF variants using LCLs from the Coriell Institute. Three LCLs carried a LRRK2 LOF variant, and 5 LCLs were normal at LRRK2. We examined protein levels using Western blot analysis and found that normalized LRRK2 protein levels are reduced by approximately half in estimated LOF lines compared with lines without LRRK2 variants (eFigures 1 and 2intheSupplement). A statistical comparison of mean normalized protein levels in normal LCLs compared with LOF carrier samples shows a significant difference in LRRK2 protein levels ( Figure 2 ), indicating that these are true LOF variants.
Discussion
We have analyzed a large set of cases with PD and controls for LOF variants in LRRK1 and LRRK2. Our results show that LRRK1 
Research Brief Report Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease
and LRRK2 LOF variants occur in the general population at an estimated frequency of approximately 0.1% to 0.2%. Interestingly, no significant differences were seen in LOF variant prevalence between cases with PD and controls. We have also shown that LRRK2 protein levels are diminished in LCLs from LRRK2 LOF carriers compared with individuals with normal LRRK2. We add more evidence to support the view that LRRK1 is unlikely to cause disease on its own, and more importantly, that pathogenic LRRK2 variants are likely to act through a gain of function rather than an LOF mechanism to cause PD.
Limitations
Among the limitations in this study, not all DNA samples were available for Sanger sequencing validation. However, because most of these variants are present in gnomAD, they are likely authentic variants. We also used stringent filters for sequencing depth to minimize false-positive findings. Although the analysis was completed in a relatively large data set, we lacked power to detect smaller effect sizes. However, causal variants typically have large effect sizes; therefore, our results imply that LRRK1 and LRRK2 LOF variants do not cause PD. We cannot exclude the possibility of small effects on PD risk.
Conclusions
Recognizing 
.).
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eAppendix. Detailed Information About Collaborators and Affiliated Groups and Projects
This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods. Variant Identification and Testing

Cohort characteristics and variant identification
Next generation sequencing data were obtained from five datasets (see Supplementary Table 1 for more details). Data processing was performed as previously described 1 . In brief, after variant calling using GATK best practices, variants were filtered for a minimal read depth of 20, genotype quality score of >20, and alternate allele ratio >25%
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. The COURAGE-PD dataset was generated using pooled sequencing, following an approach previously published study 3 .
Remaining variants were annotated using ANNOVAR 4 and filtered for loss of function variants (stop-gain, stop-loss, frameshift insertion and frameshift deletion) in LRRK1 (NM_024652) and LRRK2 (NM_198578). After filtering, variants were manually curated and bam files (if present)
were visualized using the Integrative Genomics Viewer (IGV) . All carriers of a LRRK1 or LRRK2 LOF variant were also screened for known pathogenic LRRK2 mutations and none were detected.
Statistical testing of identified LOF variants
To evaluate whether there are statistical differences between cases and controls in the frequency of LRRK1 and LRRK2 LOF variants we performed a number of tests using RVTESTS 
